Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1
- PMID: 19697415
- DOI: 10.1002/jmv.21565
Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1
Abstract
An extremely rare subset of patients infected with HIV-1 designated as "non-progressing elite controllers" appears to be able to maintain stable CD4(+) T-cell counts and a median plasma viremia below the detection limit of current ultrasensitive assays (<50-80 copies/ml of plasma) for >10 years in the absence of antiretroviral therapy. Lymphocyte subsets (CD4(+), CD8(+)), immune activation markers (HLA-DR(+), CD38(+), Beta-2-microglobulin), and HIV-specific antibody responses were longitudinally examined in four non-progressing elite controllers over more than 5 years. Two control groups of seronegative healthy individuals and untreated patients infected with HIV-1 presenting detectable viremia were also included. None of the non-progressing elite controllers displayed the high T-cell activation levels generally seen in the seropositive individuals, keeping them within the normal range. Three non-progressing elite controllers showed no significant immune system abnormalities when compared to seronegative individuals, displaying a low proportion of HIV-1-specific binding antibodies and low avidity index, similar to those observed for individuals infected recently with HIV-1. One non-progressing elite controller exhibited CD8(+) T-cell counts and beta2-M levels above normal ranges and developed a low but "mature" (high-avidity) HIV-1-specific antibody response. Thus, the non-progressing elite controllers are able to maintain normal T-cell activation levels, which may contribute to prevent, or greatly reduce, the damage of the immune system typically induced by the HIV-1 over time. They are, however, immunologically heterogeneous and very low levels of antigen exposure seem to occur in these patients, sufficient for sustaining a low, but detectable, HIV-1-specific immunity.
Similar articles
-
Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals.J Immunol. 2010 Jul 15;185(2):982-9. doi: 10.4049/jimmunol.1000221. Epub 2010 Jun 11. J Immunol. 2010. PMID: 20543099
-
Low CD4 T-cell counts despite low levels of circulating HIV: insights from the comparison of HIV-1 infected patients with a discordant response to antiretroviral therapy to patients with untreated advanced HIV-2 disease.Clin Immunol. 2007 Oct;125(1):67-75. doi: 10.1016/j.clim.2007.07.001. Epub 2007 Aug 9. Clin Immunol. 2007. PMID: 17692571
-
Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x. Scand J Immunol. 2008. PMID: 19055701
-
Elucidating the elite: mechanisms of control in HIV-1 infection.Trends Pharmacol Sci. 2009 Dec;30(12):631-7. doi: 10.1016/j.tips.2009.09.005. Trends Pharmacol Sci. 2009. PMID: 19837464 Review.
-
Control of HIV-1 replication in elite suppressors.Discov Med. 2010 Mar;9(46):261-6. Discov Med. 2010. PMID: 20350494 Review.
Cited by
-
CCR5∆32 and SDF1 3'A: Gene Variants, Expression and Influence on Biological Markers for the Clinical Progression to AIDS among HIV-1 Virus Controllers in a Mixed Population of the Amazon Region of Brazil.Int J Mol Sci. 2023 Mar 4;24(5):4958. doi: 10.3390/ijms24054958. Int J Mol Sci. 2023. PMID: 36902388 Free PMC article.
-
Parallel studies of mucosal immunity in the reproductive and gastrointestinal mucosa of HIV-infected women.Am J Reprod Immunol. 2020 Jul;84(1):e13246. doi: 10.1111/aji.13246. Epub 2020 May 8. Am J Reprod Immunol. 2020. PMID: 32301548 Free PMC article.
-
Transcriptional down-regulation of ccr5 in a subset of HIV+ controllers and their family members.Elife. 2019 Apr 9;8:e44360. doi: 10.7554/eLife.44360. Elife. 2019. PMID: 30964004 Free PMC article.
-
Natural control of HIV infection in young women in South Africa: HPTN 068.HIV Clin Trials. 2018 Oct;19(5):202-208. doi: 10.1080/15284336.2018.1531534. Epub 2018 Dec 6. HIV Clin Trials. 2018. PMID: 30522410 Free PMC article.
-
Plasmatic Levels of IL-18, IP-10, and Activated CD8+ T Cells Are Potential Biomarkers to Identify HIV-1 Elite Controllers With a True Functional Cure Profile.Front Immunol. 2018 Jul 11;9:1576. doi: 10.3389/fimmu.2018.01576. eCollection 2018. Front Immunol. 2018. PMID: 30050532 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials